What Changed

The account gives Iovance Biotherapeutics, Inc. a grant_date of September 17, 2026. It also lists stock_options_granted at 179750 and exercise_price at 10.02.

Highlights

  • The account identifies Amtagvi® as the product_name for Iovance Biotherapeutics, Inc..
  • Amtagvi® (lifileucel) is listed with approval_status of FDA-approved.
  • Iovance Biotherapeutics, Inc. is listed with treatment_centers of 95.

The Product Named in the Filing

The same account identifies Iovance Biotherapeutics, Inc.'s product_name as Amtagvi®. Amtagvi® (lifileucel) is listed with approval_status of FDA-approved.

Operating Figure to Note

Iovance Biotherapeutics, Inc. is also listed with treatment_centers of 95. For a trader following the company, the cited figures to separate are the option count, the exercise price, the grant date, the product name and the treatment-center figure.